IDEAYA Biosciences IDYA 深 沪
已收盘 10-02 16:00:00 美东时间
37.36
-0.450
-1.19%
华盛通- 最 高38.54
- 今 开38.52
- 成交量 57.90万股
- 最 低 37.00
- 昨 收 37.81
- 总市值 36.05亿
- 52周最高 42.68
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 26.20
- 委 比 -58.85%
- 总股本 9648.95万
- 历史最高 47.735
- 量 比 0.71
- 振 幅 4.07%
- 历史最低 2.95
- 每 手 1
- 风险率 3.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targe...
09-25 18:00
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57
Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $54 to $57.
09-09 21:12
美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
IDEAYA Reaches FDA Agreement On Late-Stage Trial Plan For Lung Cancer Drug, Plans Phase 3 Lung Cancer Study For IDE849 By Year-End 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849, a potential best-in-class delta-like ligand 3...
08-31 18:05
Moderna(MRNA.US)mRNA癌症疫苗重大突破引爆市场情绪！生物科技板块估值重估可能才刚开始
生物科技行业在很大程度上受到临床事件的驱动——一项三期临床试验的成功或失败，不仅可以推动直接参与其中的公司股价大幅波动，也可能影响它们所代表的整个治疗技术类别...
08-25 11:45
IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma
Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS G12D inhibitor, in patients with pancreatic ductal adenocarcinoma (PDAC) harboring both an MTAP-deleti...
08-19 18:03
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, Genentech's Phase 1 KRA...
08-19 18:00
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60
Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.
08-05 21:20
